Mucosal Therapy of Multi-Drug Resistant Tuberculosis With IgA and Interferon-γ.

Frontiers in Immunology
Andy C TranR Reljic

Abstract

New evidence has been emerging that antibodies can be protective in various experimental models of tuberculosis. Here, we report on protection against multidrug-resistant Mycobacterium tuberculosis (MDR-TB) infection using a combination of the human monoclonal IgA 2E9 antibody against the alpha-crystallin (Acr, HspX) antigen and mouse interferon-gamma in mice transgenic for the human IgA receptor, CD89. The effect of the combined mucosal IgA and IFN-γ; treatment was strongest (50-fold reduction) when therapy was applied at the time of infection, but a statistically significant reduction of lung bacterial load was observed even when the therapy was initiated once the infection had already been established. The protection involving enhanced phagocytosis and then neutrophil mediated killing of infected cells was IgA isotype mediated, because treatment with an IgG version of 2E9 antibody was not effective in human IgG receptor CD64 transgenic mice. The Acr antigen specificity of IgA antibodies for protection in humans has been indicated by their elevated serum levels in latent tuberculosis unlike the lack of IgA antibodies against the virulence-associated MPT64 antigen. Our results represent the first evidence for potential transla...Continue Reading

References

Jul 1, 1992·The Journal of Infectious Diseases·G H BothamleyJ Ivanyi
Aug 22, 1997·Science·J S SchoreyE J Brown
Aug 5, 1998·Proceedings of the National Academy of Sciences of the United States of America·Y YuanC E Barry
Oct 28, 1998·Scandinavian Journal of Immunology·R J WilkinsonJ Ivanyi
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·R TeitelbaumB R Bloom
Apr 15, 2004·Journal of Korean Medical Science·Won-Jung KohKyung Soo Lee
May 18, 2004·FEMS Immunology and Medical Microbiology·Mark A ChambersR Glyn Hewinson
Sep 10, 2005·Nature Biotechnology·Janice M ReichertMatthew C Dewitz
Mar 3, 2006·Tuberculosis·Rajko ReljicJuraj Ivanyi
Sep 26, 2006·Journal of Pharmaceutical Sciences·Wei WangSandeep Nema
Nov 25, 2006·The Lancet Infectious Diseases·Rajko Reljic, Juraj Ivanyi
Mar 13, 2010·International Journal of Pharmaceutics·Gabrielle Pilcer, Karim Amighi
Oct 12, 2010·MAbs·Janice M Reichert
Nov 5, 2010·Proceedings of the National Academy of Sciences of the United States of America·Nicole JollerAnnette Oxenius
Jan 25, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sucharitha BaluJuraj Ivanyi
Jun 8, 2012·The New England Journal of Medicine·Maria Tarcela GlerCharles D Wells
Mar 19, 2013·Cell Host & Microbe·Jacqueline M Achkar, Arturo Casadevall
Dec 3, 2014·Seminars in Immunology·John ChanJoAnne Flynn
Jan 6, 2015·Expert Opinion on Drug Delivery·Renaud RespaudNathalie Heuzé-Vourc'h
Sep 27, 2016·Cell·Lenette L LuGalit Alter
Nov 4, 2016·EMBO Molecular Medicine·Natalie ZimmermannHedda Wardemann
Nov 21, 2016·Tuberculosis·Ashley J JacobsRobert J Wilkinson
Apr 26, 2017·Proceedings of the National Academy of Sciences of the United States of America·Hao LiBabak Javid
Sep 11, 2019·Immune Network·Andy C TranRajko Reljic
Jun 26, 2020·Frontiers in Immunology·Roberto RosiniRino Rappuoli

❮ Previous
Next ❯

Citations

Mar 9, 2021·Frontiers in Immunology·Willemijn F RijninkSimone A Joosten

❮ Previous
Next ❯

Methods Mentioned

BETA
glycosylation
transgenic
ELISA
transfection
FACS
Assay
bronchoalveolar lavage
flow cytometry
lavage
antibody

Software Mentioned

Graphpad Prism
Legendplex

Related Concepts

Related Feeds